Randomised controlled trial testing effectiveness of feedback about lung age or exhaled CO combined with very brief advice for smoking cessation compared to very brief advice alone in North Macedonia: findings from the Breathe Well group

Imagem de Miniatura
Arquivos
art_GJORGJIEVSKI_Randomised_controlled_trial_testing_effectiveness_of_feedback_about_2023.PDF (1.5 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
GJORGJIEVSKI, Dragan
STAVRIKJ, Katarina
JORDAN, Rachel
ADAB, Peymane
STANOEVSKI, Gjorgji
STAMENOVA, Aleksandra
KRSTEVSKA, Emilija
SIMONOVSKA, Sara
TRPCHESKI, Fillip
ADAMS, Rachel
Citação
BMC PUBLIC HEALTH, v.23, n.1, article ID 1887, 12p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IntroductionIn 2019, smoking prevalence in North Macedonia was one of the world's highest at around 46% in adults. However, access to smoking cessation treatment is limited and no co-ordinated smoking cessation programmes are provided in primary care.MethodsWe conducted a three parallel-armed randomised controlled trial (n = 1368) to investigate effectiveness and cost-effectiveness of lung age (LA) or exhaled carbon monoxide (CO) feedback combined with very brief advice (VBA) to prompt smoking cessation compared with VBA alone, delivered by GPs in primary care in North Macedonia. All participants who decided to attempt to quit smoking were advised about accessing smoking cessation medications and were also offered behavioural support as part of the ""ACT"" component of VBA. Participants were aged >= 35 years, smoked >= 10 cigarettes per day, were recruited from 31 GP practices regardless of motivation to quit and were randomised (1:1:1) using a sequence generated before the start of recruitment. The primary outcome was biochemically validated 7-day point prevalence abstinence at 4 weeks (wks). Participants and GPs were not blinded to allocation after randomisation, however outcome assessors were blind to treatment allocation.ResultsThere was no evidence of a difference in biochemically confirmed quitting between intervention and control at 4wks (VBA + LA RR 0.90 (97.5%CI: 0.35, 2.27); VBA + CO RR 1.04 (97.5%CI: 0.44, 2.44)), however the absolute number of quitters was small (VBA + LA 1.6%, VBA + CO 1.8%, VBA 1.8%). A similar lack of effect was observed at 12 and 26wks, apart from in the VBA + LA arm where the point estimate was significant but the confidence intervals were very wide. In both treatment arms, a larger proportion reported a reduction in cigarettes smoked per day at 4wks (VBA + LA 1.30 (1.10, 1.54); VBA + CO 1.23 (1.03, 1.49)) compared with VBA. The point estimates indicated a similar direction of effect at 12wks and 26wks, but differences were not statistically significant. Quantitative process measures indicated high fidelity to the intervention delivery protocols, but low uptake of behavioural and pharmacological support. VBA was the dominant intervention in the health economic analyses.ConclusionOverall, there was no evidence that adding LA or CO to VBA increased quit rates. However, a small effect cannot be ruled out as the proportion quitting was low and therefore estimates were imprecise. There was some evidence that participants in the intervention arms were more likely to reduce the amount smoked, at least in the short term. More research is needed to find effective ways to support quitting in settings like North Macedonia where a strong smoking culture persists.Trial registrationThe trial was registered at http://www.isrctn.com (ISRCTN54228638) on the 07/09/2018.
Palavras-chave
Smoking cessation, RCT, Lung age, Carbon monoxide, Very brief advice, LMIC
URI
https://observatorio.fm.usp.br/handle/OPI/57774
Referências
  1. Akanbi MO, 2019, ADDICTION, V114, P620, DOI 10.1111/add.14518
  2. Analytica, 2019, Survey on tobacco consumption in SEE countries North Macedonia
  3. [Anonymous], 2019, WHO Report on the Global Tobacco Epidemic 2019
  4. Begh R, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0505-2
  5. Clair C, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004705.pub5
  6. Cooke F, 2008, NICOTINE TOB RES, V10, P607, DOI 10.1080/14622200801978680
  7. De Silva W., 2016, J Health Med Inform, V7, P217
  8. Dickens A, 2018, ERS PARIS INT C PRIM
  9. Drummond MB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-761
  10. Gjorgjievski D., 2020, Open Access Macedonian Journal of Medical Sciences, V8, P27, DOI 10.3889/oamjms.2020.4519
  11. Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
  12. Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
  13. Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
  14. Hristovska Mijovic B, 2022, Tobacco farming and the effects of tobacco subsidies in North Macedonia
  15. International Primary Care Respiratory Group, 2016, IPCRG teach the teacher funded by Global Bridges
  16. Kotz D, 2013, DRUG ALCOHOL DEPEN, V128, P15, DOI 10.1016/j.drugalcdep.2012.07.012
  17. Kumar N, 2021, ADDICT BEHAV, V112, DOI 10.1016/j.addbeh.2020.106612
  18. Lin PR, 2013, J PUBLIC HEALTH-UK, V35, P375, DOI 10.1093/pubmed/fdt018
  19. McBride CM, 2003, HEALTH EDUC RES, V18, P156, DOI 10.1093/her/18.2.156
  20. McCaul KD, 2006, ADDICT BEHAV, V31, P42, DOI 10.1016/j.addbeh.2005.04.004
  21. MORRIS JF, 1985, PREV MED, V14, P655, DOI 10.1016/0091-7435(85)90085-4
  22. National Centre for Smoking Cessation and Training, 2019, Standard treatment programme
  23. Nikovska DG., 2014, GJMEDPH, V3, P1
  24. Ojedokun J, 2013, J Gen Pract, V1, P123, DOI [10.4172/2329-9126.1000123, DOI 10.4172/2329-9126.1000123]
  25. Parkes G, 2008, BMJ-BRIT MED J, V336, P598, DOI 10.1136/bmj.39503.582396.25
  26. Parrott S, 1998, THORAX, V53, pAS1
  27. Reitsma MB, 2021, LANCET, V397, P2337, DOI 10.1016/S0140-6736(21)01169-7
  28. Ripoll J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-322
  29. Shahab L, 2012, National Centre for Smoking Cessation Training-Briefing 7
  30. Spasova T, 2018, Tobacotaxation
  31. StataCorp, 2019, Stata Statistical Software: Release
  32. Stead LF, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub3
  33. Stead LF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub4
  34. Van Schayck OCP, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0039-5
  35. West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x
  36. West R, 2008, EUR RESPIR REV, V17, P199, DOI 10.1183/09059180.00011005
  37. World Health Organisation, 2020, WHO package of essential noncommunicable (pen) disease interventions for primary health care
  38. World Health Organisation, 2019, WHO REPORT GLOBAL TO

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/09